Tecentriq is an intravenous humanized monoclonal antibody that targets PD-L1, an immune checkpoint protein expressed on certain tumor cells (TC) and tumor-infiltrating immune cells (IC). It inhibits interaction between PD-L1 and PD-1. Tecentriq is FDA-approved for second-line treatment of locally advanced or metastatic non-small cell lung cancer. Tecentriq is also approved to treate urothelial carcinoma.

If you have a Hayes login, click here to view the full report on the Knowledge Center.